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Abstract
The endogenous synthesis of morphine has been clearly
demonstrated throughout the phylogenesis of the nervous
system of mammals and lower animals. Endogenous mor-
phine, serving as either a neurotransmitter or neurohormone,
has been demonstrated in the nervous system of both verteb-
rates and invertebrates. As one of the effects of exogenous
morphine is the modulation of pain perception, we investi-
gated the effects that the depletion of endogenous morphine
had on nociceptive transmission. The immunoneutralization of
endogenous morphine from brain extracellular spaces was
obtained through the intracerebroventricular administration of
affinity purified anti-morphine IgG to mice, which then under-
went the hot plate test. Endogenous morphine immunoneut-
ralization decreased thermal response latency and attenuated
the anti-nociceptive effect of the mu selective agonist DAMGO
in hot plate test suggesting that endogenous morphine is
involved in pain modulation.
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The presence of endogenous morphine (eM) in various
tissues from mammals and lower animals has been proven
using highly sensitive techniques such as immunological
recognition, liquid and gas chromatographic retention times
and mass spectrometry (Gintzler et al. 1976; Goldstein et al.
1985; Cardinale et al. 1987; Stefano et al. 1993; Liu et al.
1997; Sonetti et al. 1999; Goumon and Stefano 2000;
Stefano et al. 2000). The morphine corresponding HPLC
fractions was analyzed by gas-chromatography/mass-spect-
rometry (GC/MS) and were found to be identical to synthetic
morphine by different authors (Donnerer et al. 1986; Guarna
et al. 1998)1 . These studies conclusively proved that mor-
phine alkaloid is endogenous to the mammalian brain.
The pathways of morphine biosynthesis have been estab-
lished in the oppium poppy and animal tissue starting from
L-tyrosine. Coclaurine, tetrahydropapaveroline, reticuline,
salutaridine, thebaine and codeine are the main intermediates
in the poppy plant, and similar pathways have been either
demonstrated or presumed in mammals (Weitz et al. 1987).
The conversion of salutaridine, thebaine and codeine into
morphine has been demonstrated in several rat tissues,
including the brain (Donnerer et al. 1986). Radiolabeled
reticuline is transformed into salutaridine by rat liver
microsomes in vitro (Weitz et al. 1987; Kodaira and Spector
1988) and a similar conversion has been observed in vivo
(Weitz et al. 1987).
Morphine immunoreactivity has been demonstrated inside
the cell body, fibers and terminals of neurons in different
brain areas of the rat (Bianchi et al. 1993), mouse (Gintzler
et al. 1978) and humans, and has been localized by electron
microscopy in nerve terminals forming synaptic contacts
(Bianchi et al. 1994). The immunohistochemical study of eM
distribution in the mouse brain revealed the simultaneous
presence of naturally occurring morphine in different parts
Received April 23, 2001; revised manuscript received October 9, 2001;
accepted October 13, 2001.
Address correspondence and reprint requests to E. Bianchi, Labora-
torio di Farmacologia Molecolare, Dipartimento di Neuroscienze, Uni-
versita` di Siena, Via A. Moro 6, 53100 Siena, Italy.
E-mail: emacom@comune.siena.it
Abbreviations used: EKC, ethylketocyclazocine; eM, endogenous
morphine; i.c.v., intracerebroventricular; GC/MS, gas chromatography/
mass spectometry; PBS, phosphate-buffered saline; SIM, selected ion
monitoring.
Journal of Neurochemistry, 2002, 80, 271–277
Ó 2002 International Society for Neurochemistry, Journal of Neurochemistry, 80, 271–277 271
of the pain modulatory system. Endogenous morphine was
localized in brainstem regions involved in the descending
pain inhibitory pathway, such as midbrain periacqueductal
gray matter including nucleus raphe magnus and their major
caudal projection target, the rostral ventral medulla complex
(Gintzler 1978). Neuron depolarization by high potassium
concentrations caused release of eM from eel chromaffin
cells (Epple et al. 1993) and rat brain slices (Guarna 1998).
This effect was calcium dependent.
Although eM meets some of the criteria of mammalian
neurotransmitters, at this time, the function of eM in
mammalian nervous systems is largely unknown. Many
studies examining opiate/opioid functions do not differentiate
the effects of endogenous opioid peptides from eM or they
examine opiate mediated processes by the application of
exogenous morphine. It is therefore important to examine the
events which may be modulated by eM, and determine if
highly selective processes exist that exclusively involve eM
signaling. In this regard, exogenous morphine application
and particularly eM, may be involved in the regulation of
certain kinds of pain (Donnerer et al. 1987). An effect of
exogenous morphine is the modulation of pain perception
with an increase in the threshold of noxious stimuli (Matthes
et al. 1996; Elmer et al. 1998). In this study we have
investigated the effects induced on hot plate test by the
in vivo immunoneutralization of eM in mice. Affinity purified
anti-morphine IgG was injected by intracerebroventricular
(i.c.v.) administration into mice (Ohno et al. 1988; Kavaliers
and Yang 1989; Obal et al. 1992; Opp and Krueger 1994;
Callahan et al. 2000) to determine the effects of the
immunoneutralization of eM on thermal nociception.
Materials and methods
Animals
Sexually mature albino male CD)1 mice (Charles River, Italy)
weighing 30–40 g were used. They were housed 3–4 per cage at 22°C
with a 12-h light/dark cycle and free access to food and water for one
week before the experiments. Testing was routinely performed
between 09.00 and 15.00 and independent groups of mice were used
for each experimental condition. Commercially bottled mineral
water, all of the same lot, was used throughout the experiments.
Specimens of food and water were randomly sampled and analysed
by GC/MS. The procedures used in this study were in strict
accordance with legislation on the use and care of laboratory animals.
GC/MS determination of endogenous morphine in mouse brains
Mouse brains were used for GC/MS detection of eM by a previously
described method (Guarna 1998). Briefly, the brains were homo-
genized using a blade blender and then added with a saturated
solution of sulfate ammonia and acidified with 1 mL of 3M HCL at
121°C for 30 min (Felby et al. 1974). The sample was cooled,
filtered through Buchner funnel using a Whatman n°1 filter
paper. The obtained fraction was set to pH 9 and submitted to
morphine extraction by solid phase on Bond Elut Certify columns
(Varian, Harbor City, CA, USA) containing 300 mg of active
silica. The eluate was collected in glass tubes to which an external
standard consisting of nalorphine solution (250 ng/mL) in methanol
was added. The samples were dried under a stream of warm air
together with a series of standard solutions containing morphine from
10 ng/mL to 0. 5 ng/mL and nalorphine (25 ng). The dried samples
were derivatized (Knapp 1979) by adding of a 20% solution of 50 lL
of N-methyl-N-trimethyl-silyltrifluoroacetamide (Pierce, Rockford,
IL, USA) in toluene; 1 lL of each derivatized sample was submitted
to GC/MS analysis which was performed using a Hewlett Packard
5890 series II gas chromatograph coupled with a Hewlett Packard
5791 MS detector. The analysis was performed in selected ion
monitoring (SIM) mode; derivatized morphine was identified by
fragments 429, 414 and 236 and derivatized nalorphine by fragments
455, 440 and 414. The quantifier ion was 429 for morphine and 455
for nalorphine. Previous GC/MS analysis of standard solutions of
derivatized morphine and nalorphine validated both the retention
times and the characteristic ions for this substance.
Drugs
DAMGO, nalorphine HCl, codeine and DPDPE were purchased
from Sigma Chemicals (St Louis, MO, USA). b-endorphin, met-
enkephalin, endomorphin-1 and endomorphin-2 from the America
Peptide Company (Sunnyvale, CA, USA).2,3 EKC was purchased from
Sterling-Winthrop (Collegeville, PA, USA).
The purification of anti-morphine antibody
A polyclonal antibody to morphine-6-keyhole limpet hemocyanin
was raised in sheep (Biogenesis). After the fractionation of IgGs
from the serum with ammonium sulfate, anti-morphine IgG (3 mL)
was applied to an affinity column previously prepared by the
attachment of morphine 6-hemosuccinate (Simon et al. 1972) to
CNBR activated 4B Sepharose (Pharmacia) according to the
manufacturer’s instructions. The column was then eluted with
0.5 M acetic acid, ph 2.7 (Spratt and Jones 1976). The IgGs were
separated from normal sheep serum (Sigma) using a purification kit
(Bio-Rad Econo-Pac, serum IgG purification kit). The dialyzed
concentrated IgGs gave a final protein concentration of 1.5 lg/lL
for anti-morphine IgG and 0.4 lg/lL for normal serum. The cross-
reactivity of the antibody was characterized by the competitive
inhibition of [3H]morphine (35 Ci/mM; Amersham, Milan, Italy)4 by
various unlabeled compounds with anti-morphine IgGs. The
compounds assayed were codeine, b-endorphin, met-enkephalin,
endomorphin-1, endomorphin-2 and DAMGO. Cross-reactivity was
expressed as the quantity of cross-reactive compound that inhibited
antibody binding by 50% divided by the quantity of morphine that
inhibited antibody binding by 50%.
Anti-morphine antibody cross-reactivity
We generated an anti-morphine antibody for use in our in vivo
experiments. To demonstrate the specificity of the anti-morphine
antibody we measured the cross-reactivity of the affinity purified
anti-morphine IgG with other compounds through the competitive
inhibition of [3H]-morphine binding. The cross-reactivity of the
affinity purified anti-morphine IgG (IC50,compound/IC50 MF) was:
morphine (1), codeine (> 9000), DAMGO (> 10 0000), b-endor-
phin (> 10 0000), met-enkephalin (> 10 0000), endomorphin-1
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(> 10 0000), endomorphin-2 (> 10 0000). This demonstrates that
our antibody exhibits minimal cross-reactivity to codeine,
DAMGO and endogenous opioid peptides.
Habituation procedure
All the animals were previously habituated to the laboratoty
according to Abbott et al. 1986).
Intracerebroventricular administration
Immunoglobulins were injected in a final volume of 5 lL
phosphate-buffered saline (PBS) and the mice were not
anesthetized during these procedures. The i.c.v. injections were
performed into the right and left cerebral ventricle according to
the method described by Haley and McCormick (1957) injecting
2.5 lL in each side of the brain.
Hot-plate test
The test was based on the one described in Eddy and Leimbach
(1953). A glass cylinder (16 cm high, 16 cm diameter) was used to
keep the mice on the hot plate, which was at a temperature of
50  0.5°C. Here we have used lower temperatures in hot plate test
(50°C instead of 54°C) to reveal possible subtle alterations that may
occur in basal nociception. The licking latency was measured
immediately prior i.c.v. injections, at starting time and at 15 min
intervals for 90 min with a 30-s cut-off to prevent tissue damage.
The endpoint for the licking response was the first paw lick whether
it was lick of the front or rear paw. Anti-nociception was seen as
increased latencies to the responses evaluated while increased
nociception was seen by shorter latencies. Hot plate sessions were
videotaped for later measurement by an observer blind to the treatment.
Motor coordination test
Rota-rod test
Up to five mice were tested simultaneously on the apparatus, with a
rod rotating speed of 16 r.p.m. The integrity of motor co-ordination
was assessed on the basis of the number of falls from the rod in 30 s
according to Vaught et al. (1985). Their performance was measured
before, and at 15, 30 and 45 min after the beginning of the
experiments.
Spontaneous activity meter
IgG and PBS pre-treated mice were used. Locomotor activity was
quantified using a type-S Animex activity meter (LKB, Farad,
Sweden) set to maximum sensitivity. Mice were placed on the meter
which transformed their movements into digital signals. Activity
counts were made every 15 min for 45 min.
Experiment I – effects of eM immunoneutralization
on thermonociception
The administration of exogenous morphine in vivo has been shown
to induce thermal analgesia in the hot plate in mice (Matthes
1996). Therefore, its counterpart, eM, may be considered to induce
an analogous effect. The effects of eM on thermal nociception
have been studied in vivo by immunoneutralization of the
endogenous alkaloid. This was obtained through the i.c.v.
administration of affinity purified anti-morphine IgG to mice
which then underwent hot plate test.
Independent grsoups of mice (n  10 each) were i.c.v. injected
with either PBS, affinity purified anti-morphine IgG or affinity
purified normal sheep IgG. The IgGs (0.05 lg, 0.2 lg, 2 lg and
5 lg) were administered 5 min before testing in the hot plate.
Experiment II – GC/MS determination of IgG bound eM
in mouse brains
In order to extract the IgG bound eM from the mice brains, the
method modified by Takahashi was used (Takahashi and Das
1985). Independent groups of mice (n  10 each) previously
administered with anti-morphine IgG (5 lg, 2 lg, 0.2 lg,
0.05 lg, 0.005 lg) or PBS were submitted to hot plate test
(experiment I). At the 45th min of the test run (experiment I), the
brains were extracted from mice under deep anesthesia, the
meninges peeled, the brains minced into small pieces and
homogenized at 4°C with 10 volume (wt/vol) of PBS pH 7.2 in
the presence of protease inhibitor (2 mM phenylmethylsulfonyl-
fluoride; Sigma, Milan, Italy). The homogenates were centrifuged
at 1000 g5 for 5 min and the pellets were washed 20 times with
PBS, resuspended 1 : 20 in the same medium and dyalized
against PBS (50-kDa molecular weight cut-off, Spectra/Por
membranes; Spectrum, CA, USA)6 . The IgGs were separated from
the dyalized sample using a purification kit (Bio-Rad Econo-Pac,
serum IgG purification kit). The eluted IgGs were boiled to
separate the antibody from the antigen and centrifuged (30 000 g)
at 4°C for 45 min. The supernatant was ultrafiltered, lyophilized
and analyzed by GC/MS for morphine determination.
Experiment III – reversion of DAMGO, EKC or DPDPE
induced analgesia by anti-morphine IgG
In order to study the effects of i.c.v. administration of anti-morphine
IgG on the analgesia induced by the l agonist DAMGO or the j
agonist ethylketocyclazocine (EKC) or the d agonist [D-Pen2,
D-Pen5] enkephalin (DPDPE), immediately before hot plate test,
different doses of DAMGO (1–10 mg/kg i.v.), EKC (0.5–10 mg/kg,
s.c.) or DPDPE (1–80 lg/mouse i.t.) were injected into PBS or
anti-morphine (2 lg) independent groups of mice (n  10 each)
i.c.v. injected 5 min before starting time.
Statistics
The data were analyzed with a mixed design repeated measures
analysis of variance and post hoc comparisons. A Dunnet multiple
comparison test was used to determine the significance of differ-
ences in the hot plate response after different treatment with respect
to controls.
Controls
The animals which underwent the hot-plate test were submitted to
paw temperature measurement 24 h, 10 min and 1 min before
testing. The temperature was measured with an infrared thermom-
eter (Omega, Standford, CT).
At the conclusion of the experiments, the mice were anesthe-
tized and their brains excised which were then cut coronally to
check the visible path of i.c.v. injection. Only the data from mice
in which the injection was correctly located within the ventricles
was considered.
Levels of eM were determined in brains extracted from a different
group of mice submitted to i.c.v. administration of PBS at the
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following times: 15 min before (control), 5 and 30 min after i.c.v.
injection.
Results
GC/MS determination
The brain content of eM quantified by GC/MS was
0.31  0.012 ng/g (mean  SE, n  10; Fig. 1). These levels
are similar to those previously reported for the rats (Guarna
1998). No morphine contamination was found in the blank
samples, food and water.
Experiment I – effects of eM immunoneutralization
on thermonociception
The effects of different in vivo pre-treatments on nocicep-
tive threshold in the hot plate test are reported in Fig. 2.
The i.c.v. injection of 5 and 2 lg anti-morphine IgG
resulted in a highly significant decrease in licking latency
with respect to the control injection of PBS. Maximum
nociceptive effects were evident at 45 and 60 min after the
starting time. Lower doses (< 0.2 lg) lacked a hyperal-
gesic effect. In contrast, pre-treatment with normal sheep
IgGs at the same concentrations did not produce any
appreciable change in licking latency compared to the
controls (Fig. 3).
Rota-rod test
No significant differences were observed in the number of
falls at different times between PBS and IgG pre-treated
mice.
Spontaneous activity meter
No difference in the activity counts of IgG pre-treated and
control mice (i.c.v. PBS) was detected. Therefore, no motor
disturbances were observed in either test.
Fig. 1 Chromatographic plot of mouse
brain morphine content [derivatized mor-
phine retention time (RT)  11.53; deriv-
atized nalorphine RT  12.39]. In the
middle, a morphine calibration curve that
was constructed by plotting the morphine/
nalorphine peak area ratio (X axis) versus
the quantity of morphine (Y axis).
Fig. 2 Hot plate test-latencies for nocicep-
tive responses in the hot plate test in mice
pre-treated with either PBS, anti-morphine
IgGs or or normal sheep IgGs. **Significant
statistical difference at p < 0.01 versus
PBS. *Significant statistical difference at
p < 0.05 versus PBS. Vertical bars are
the corresponding SEM. n, PBS; j, anti-
morphine IgG (0.05 lg); m, anti-morphine
IgG (0.2 lg); d, anti-morphine IgG (2 lg);
e, anti-morphine IgG (5 lg).
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Skin temperature
The skin temperature of the paws remained unchanged after
microinjection of IgG and PBS (a < 0.05 all conditions, data
not shown).
Endogenous morphine levels in brain before and after
PBS i.c.v. administration
The brain content of eM quantified by GC/MS at different
times after PBS central injection (Table 1) did not show any
significant differences with respect to controls (15 min
before administration).
Experiment II – GC/MS determination of IgG bound
em in mouse brains
Immunoglobulin bound eM was extracted and determined by
GC/MS in the brains of mice which were subjected to the hot
plate test after anti-morphine IgG administration. The results
are reported in Table 2. In the brains (Table 2) IgG bound
eM appeared to be correlated with licking latency. The
hyperalgesic effect increases with the quantity of eM bound
by anti-morphine IgG previously i.c.v. administered to mice.
Higher doses of anti-morphine IgG (2–5 lg) reached the
maximum hyperalgesic effect. At higher doses of anti-mor-
phine IgG, the quantity of eM bound to anti-morphine IgG
was constant; therefore it can be surmised that the unbound
antibody does not modify the hyperalgesic effect. No eM
bound IgGs were detected in the brains from the mice which
had undergone the hot plate test after the i.c.v. administration
of PBS. Therefore, it can be concluded that anti-morphine
antibodies which behave as antagonists in vivo do not
naturally occur in mouse brain.
Experiment III – reversion of DAMGO, EKC
or DPDPE induced analgesia by anti-morphine IgG
Administration of anti-morphine IgG to mice induces a right
shift of the DAMGO dose-effect curve in hot-plate test
(Fig. 4a). The value of DAMGO ED50 significantly increases
when anti-morphine IgG (2 lg) was previously administered
to mice. No significant right shift of the dose-effect curve was
obtained after EKC or DPDPE administration (Fig. 4b–c).
Discussion
The present study demonstrates the presence of naturally
occurring morphine alkaloid in the mouse brain at concen-
trations similar to those found in the rat brain (Donnerer
1986; Guarna 1998). The morphine corresponding HPLC
fractions were analyzed by GC/MS and found to be identical
to synthetic morphine.
The i.c.v. administration of affinity-purified anti-morphine
IgG which exhibited minimal cross-reactivity with codeine
and opioid peptides, induced a hyperalgesic response in mice
Table 1 GC/MS determination of eM levels in mouse brains before
and after PBS central injection
15 min before
(ng/g brain tissue)
5 min after
(ng/g brain tissue)
30 min after
(ng/g brain tissue)
0.29  0.02 0.33  0.04 0.30  0.03
Each value of the columns represents the brain content of eM quan-
tified by GC/MS and expressed as mean value  SEM from groups of
10 mice each.
Table 2 GC/MS determination of IgG bound eM from mice which
were administered previously with increasing doses of anti-morphine
IgG and submitted to the hot plate test
IgG-bound eM
(pg/g)
Licking latency
(s)
Anti-morphine IgG
dose (lg)
543 6.9  0.6** 5
536 7.1  0.8** 2
190 10.3  1.1* 0.2
105 12.1  1.2 0.05
nd 11.9  0.9 0.005
Each value of the licking latency column represents the mean licking
latency measured at 45 min which corresponds at the maximum
nociceptive effect. At the end of the 45 min licking latency measure-
ment, the brains were extracted from the mice in order to determine
IgG bound morphine. nd, not detectable; **significance level of 0.01;
*significance level of 0.05.
Fig. 3 Hot plate test-latencies for nocicep-
tive responses in the hot plate test in mice
pretreated with either PBS or normal sheep
IgGs. Vertical bars are the corresponding
SEM. r, PBS; n, normal sheep IgG (0.05
lg); X, normal sheep IgG (0.2 lg); e, nor-
mal sheep IgG (2 lg); j, normal sheep IgG
(5 lg).
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subjected to thermal nociception. As shown by the licking
latency in the hot plate test, the nociceptive threshold in
response to thermal stimulus was significantly lowered by anti-
morphine IgG with respect to controls. The hyperalgesic
effects obtained after anti-morphine IgG pre-treatment corre-
late with the quantity of eM bound to the anti-morphine IgG
extracted from the brains of mice previously i.c.v. injected with
different doses of anti-morphine IgGs. At the highest anti-
morphine IgG doses tested, the maximum hyperalgesic effect
was reached whereas the quantity of eM extracted from the
immune complex did not change at these doses. The observed
hyperalgesic effect increased with the quantity of eM bound to
the antibody, whereas it did not appear to be modified by
higher doses of anti-morphine IgGs. The levels of morphine
endogenously present in the mouse brain might be considered
comparable to a subcutaneous administration of 30 lg/kg
exogenous morphine according to a 2–3% brain uptake of the
intravenous morphine dose (Glare and Walsh 1991) and a 70%
bioavailability (Miyamoto et al. 1993). This dose appeared to
be equipotent in eliticing inhibitory/analgesic and exitatory/
hyperalgesic effects (Crain and Shen 2001). As reported in the
findings by Shen and Crain (2001), morphine injected at low
doses, that is less than 30 lg/kg, induces a hyperalgesic
response mediated by the activation of opioid receptor coupled
Gs protein (Crain and Shen 1998). This effect appears to be
dose dependent. Therefore, the hyperalgesic effect we
observed in the hot plate test after eM immunodepletion
might be ascribed to a decrease in eM levels present in the
mouse brain extracellular spaces with respect to the basal
morphine level which is maintained by the continuos release of
eM (0.1–0.5 ng/g/min, Guarna 1998) by nerve terminals. No
change was induced by non-immune sheep IgG pre-treatment
at different doses thereby demonstrating that higher protein
levels do not affect nociceptive response. No naturally
occurring anti-morphine antibodies could be detected in the
control mice when administered with PBS. Endogenous
morphine immunoneutralization was found to significantly
attenuate the anti-nociceptive effect of DAMGO, a l selective
agonist, as showed by the right shift of the DAMGO dose-
effect curve. In contrast to DAMGO, no significant right shift
of the dose-effect curve was obtained when different doses of
the selective j agonist EKC or of the selective d agonist
DPDPE were administered to mice previously treated with
anti-morphine IgG. Therefore j and d receptors might not to
be involved in the anti-morphine IgG effect.
Endogenous morphine is present (Gintzler 1978; Bianchi
1993, 1994) in the mammalian brain regions which are
involved in the modulation of pain transmission (Willis and
Westlund 1997) where opioids and opiates act by modulating
the descending inhibitory pathway of nociceptive transmis-
sion (Fields et al. 1991). These findings, taken as a whole,
suggest that eM may play a role in the modulation of thermal
nociception.
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